Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Characteristics and Long-Term Outcome of Patients with Systemic Immunoglobulin Light-Chain Amyloidosis

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Joint Mobility and Physical Function of Danish Hemophilia Patients: A Three-Wave Panel Study Spanning 24 Years

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Myeloproliferative Neoplasms in Danish Twins

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognosis of Allogeneic Haematopoietic Stem Cell Recipients Admitted to the Intensive Care Unit: A Retrospective, Single-Centre Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Haemostasis and safety measures before lumbar puncture in the haematology ward: the Danish routines

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pulmonary Arterial Wedge Pressure at Rest and During Exercise in Healthy Adults: A Systematic Review and Meta-analysis

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Background/Aims: Immunoglobulin light-chain (AL) amyloidosis is a systemic disorder that causes progressive organ dysfunction. The optimal treatment strategy requires accurate patient stratification with an emphasis on the extent of cardiac involvement. Reports on its prognosis are sparse and predominantly originate from highly selected centers. We aimed to evaluate patient characteristics and outcomes in a cohort treated at a single center. Methods: This is a single-center retrospective study of 63 consecutive patients diagnosed with AL amyloidosis between January 2000 and December 2012. Patients were evaluated by treatment strategy and cardiac involvement. Results: The mean age at diagnosis was 61.4 years (±8.9), and 39 patients (62%) were male. Thirty-two (51%) patients presented with cardiac amyloid involvement (CA) and the remaining 31 (49%) had noncardiac amyloidosis (NCA). The median follow-up time was 12.7 months (0.3-90.8), and 38 (60%) patients died during follow-up. The median overall survival (OS) was 29 months (95% CI 12.1-57.2) and the OS was not significantly lower for patients with CA compared to NCA (log-rank = 0.21). Conclusion: The prognosis in AL amyloidosis is grave, but the outcome with treatment in the current series was comparable to those in series from larger centers. CA did not significantly predict the OS. © 2014 S. Karger AG, Basel.

Original languageEnglish
JournalActa Haematologica
Volume133
Issue number4
Pages (from-to)336-346
Number of pages11
ISSN0001-5792
DOIs
Publication statusPublished - 16 Dec 2014

ID: 45026421